Combining AstraZeneca's 'good' cholesterol booster with PCSK9 inhibition shows promise in heart disease

Most heart disease drugs are aimed at reducing "bad" low-density lipoprotein (LDL) cholesterol. But AstraZeneca figures that strategy alone still leaves patients with a meaningful risk of suffering major cardiovascular events.

So, scientists at the British pharma are working on boosting "good" high-density lipoprotein cholesterol (HDL-C) as a strategy for reducing the risk of heart disease.